A Mutation in Human Immunodeficiency Virus Type 1 Protease, N88S, That Causes in Vitro Hypersensitivity to Amprenavir

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2001 Feb 7

PMID 10756056

Citations 29

Authors

R Ziermann

K Limoli

K Das

E Arnold

C J Petropoulos

N T Parkin

Affiliations

Soon will be listed here.

Abstract

Amprenavir (Agenerase, 141-W94, VX-478) is a human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PRI) recently approved for the treatment of HIV-1 infection in the United States. A major cause of treatment failure is the development of resistance to PRIs. One potential use for amprenavir is as salvage therapy for patients for whom treatment that includes one (or more) of the other four currently approved PRIs-saquinavir, indinavir, ritonavir, and nelfinavir-has failed. We evaluated the cross-resistance to amprenavir of viruses that evolved during treatment with the two most commonly prescribed PRIs, nelfinavir and indinavir. Unexpectedly, a dramatic increase in susceptibility (2.5- to 12. 5-fold) was observed with 20 of 312 (6.4%) patient viruses analyzed. The most pronounced increases in susceptibility were strongly associated with an N88S mutation in protease. All viruses that carried the N88S mutation were hypersensitive to amprenavir. Site-directed mutagenesis studies confirmed the causal role of N88S in determining amprenavir hypersensitivity. The presence of the N88S mutation and associated amprenavir hypersensitivity may be useful in predicting an improved clinical response to amprenavir salvage therapy.

Citing Articles

Non-active site mutants of HIV-1 protease influence resistance and sensitisation towards protease inhibitors.

Bastys T, Gapsys V, Walter H, Heger E, Doncheva N, Kaiser R Retrovirology. 2020; 17(1):13.

PMID: 32430025 PMC: 7236880. DOI: 10.1186/s12977-020-00520-6.

Collinearity of protease mutations in HIV-1 samples with high-level protease inhibitor class resistance.

Babrzadeh F, Varghese V, Pacold M, Liu T, Nyren P, Schiffer C J Antimicrob Chemother. 2012; 68(2):414-8.

PMID: 23085775 PMC: 3543120. DOI: 10.1093/jac/dks409.

HIV-1 antiretroviral resistance: scientific principles and clinical applications.

Tang M, Shafer R Drugs. 2012; 72(9):e1-25.

PMID: 22686620 PMC: 3689909. DOI: 10.2165/11633630-000000000-00000.

Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibility.

Santos A, Tebit D, Lalonde M, Abecasis A, Ratcliff A, Camacho R Antimicrob Agents Chemother. 2012; 56(5):2719-25.

PMID: 22330918 PMC: 3346603. DOI: 10.1128/AAC.06079-11.

A Guide to HIV-1 Reverse Transcriptase and Protease Sequencing for Drug Resistance Studies.

Shafer R, Dupnik K, Winters M, Eshleman S HIV Seq Compend. 2012; 2001:1-51.

PMID: 22324021 PMC: 3274565.

References

Patick A, Duran M, Cao Y, Shugarts D, Keller M, Mazabel E . Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother. 1998; 42(10):2637-44. PMC: 105911. DOI: 10.1128/AAC.42.10.2637. View

Hecht F, Grant R, Petropoulos C, Dillon B, Chesney M, Tian H . Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med. 1998; 339(5):307-11. DOI: 10.1056/NEJM199807303390504. View

Sadler B, Hanson C, Chittick G, Symonds W, Roskell N . Safety and pharmacokinetics of amprenavir (141W94), a human immunodeficiency virus (HIV) type 1 protease inhibitor, following oral administration of single doses to HIV-infected adults. Antimicrob Agents Chemother. 1999; 43(7):1686-92. PMC: 89344. DOI: 10.1128/AAC.43.7.1686. View

Palmer S, Shafer R, Merigan T . Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 1999; 13(6):661-7. PMC: 2566777. DOI: 10.1097/00002030-199904160-00006. View

Parkin N, Lie Y, Hellmann N, Markowitz M, Bonhoeffer S, Ho D . Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. J Infect Dis. 1999; 180(3):865-70. DOI: 10.1086/314928. View

Boden D, Hurley A, Zhang L, Cao Y, Guo Y, Jones E . HIV-1 drug resistance in newly infected individuals. JAMA. 1999; 282(12):1135-41. DOI: 10.1001/jama.282.12.1135. View

Little S, Daar E, DAquila R, KEISER P, Connick E, Whitcomb J . Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA. 1999; 282(12):1142-9. DOI: 10.1001/jama.282.12.1142. View

Petropoulos C, Parkin N, Limoli K, Lie Y, Wrin T, Huang W . A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother. 2000; 44(4):920-8. PMC: 89793. DOI: 10.1128/AAC.44.4.920-928.2000. View

Gong Y, Robinson B, Rose R, Deminie C, Spicer T, Stock D . In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother. 2000; 44(9):2319-26. PMC: 90064. DOI: 10.1128/AAC.44.9.2319-2326.2000. View

10.

Adachi A, Gendelman H, Koenig S, Folks T, Willey R, Rabson A . Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol. 1986; 59(2):284-91. PMC: 253077. DOI: 10.1128/JVI.59.2.284-291.1986. View

11.

Sarkar G, Sommer S . The "megaprimer" method of site-directed mutagenesis. Biotechniques. 1990; 8(4):404-7. View

12.

Coffin J . HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995; 267(5197):483-9. DOI: 10.1126/science.7824947. View

13.

Larder B, Kemp S, Harrigan P . Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science. 1995; 269(5224):696-9. DOI: 10.1126/science.7542804. View

14.

Partaledis J, Yamaguchi K, Tisdale M, Blair E, Falcione C, Maschera B . In vitro selection and characterization of human immunodeficiency virus type 1 (HIV-1) isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol. 1995; 69(9):5228-35. PMC: 189353. DOI: 10.1128/JVI.69.9.5228-5235.1995. View

15.

Livington D, Pazhanisamy S, Porter D, Partaledis J, Tung R, Painter G . Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis. 1995; 172(5):1238-45. DOI: 10.1093/infdis/172.5.1238. View

16.

St Clair M, Millard J, Rooney J, Tisdale M, Parry N, Sadler B . In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res. 1996; 29(1):53-6. DOI: 10.1016/0166-3542(95)00916-7. View

17.

Smidt M, Potts K, Tucker S, Blystone L, Stiebel Jr T, Stallings W . A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. Antimicrob Agents Chemother. 1997; 41(3):515-22. PMC: 163743. DOI: 10.1128/AAC.41.3.515. View

18.

Lazdins J, Mestan J, Goutte G, Walker M, Bold G, Capraro H . In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis. 1997; 175(5):1063-70. DOI: 10.1086/520352. View

19.

Tucker S, Stiebel Jr T, Potts K, Smidt M, Bryant M . Estimate of the frequency of human immunodeficiency virus type 1 protease inhibitor resistance within unselected virus populations in vitro. Antimicrob Agents Chemother. 1998; 42(2):478-80. PMC: 105443. DOI: 10.1128/AAC.42.2.478. View

20.

Hirsch M, Conway B, DAquila R, Johnson V, Brun-Vezinet F, Clotet B . Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998; 279(24):1984-91. DOI: 10.1001/jama.279.24.1984. View